{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T13:43:27Z","timestamp":1759412607846},"reference-count":23,"publisher":"American Society for Microbiology","issue":"5","license":[{"start":{"date-parts":[[2005,5,1]],"date-time":"2005-05-01T00:00:00Z","timestamp":1114905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Vaccine Immunol"],"published-print":{"date-parts":[[2005,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>MenBvac and Menjugate are safe and efficacious vaccines. The purpose of this study was to evaluate safety and immunogenicity of the combination (MenB\/C) of the lyophilized active components of the conjugated group C vaccine Menjugate when reconstituted with the full liquid group B outer membrane vesicle vaccine MenBvac compared to MenBvac and Menjugate given separately. At 6-week intervals, healthy adults were given one dose of MenB\/C followed by two doses of MenBvac (MenB\/C group), three doses of MenBvac (MenB group), or one dose of Menjugate and two doses of placebo (MenC group). Injection site reactions were frequent in all groups. However, most reactions were short lasting and mild or moderate in intensity, and the vaccines were found to be well tolerated, with no vaccine-related serious adverse events. MenB\/C was immunogenic with regard to both serogroup B and C meningococci. Both the serum bactericidal assay and the enzyme-linked immunosorbent assay analyses showed that the immune responses of the combination vaccine were similar to the immune responses of its separate components MenBvac and Menjugate for both serogroup B and C. In conclusion, the combined MenB\/C vaccine is safe and immunogenic. The two vaccines do not interact negatively with each other and can easily be administered in the same syringe. The induced immune responses suggest that the combined vaccine is likely to confer protection against systemic group B disease caused by the vaccine strain as well as against group C meningococcal disease.<\/jats:p>","DOI":"10.1128\/cdli.12.5.599-605.2005","type":"journal-article","created":{"date-parts":[[2005,5,5]],"date-time":"2005-05-05T17:23:00Z","timestamp":1115313780000},"page":"599-605","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":7,"title":["Combined Administration of Meningococcal Serogroup B Outer Membrane Vesicle Vaccine and Conjugated Serogroup C Vaccine Indicated for Prevention of Meningococcal Disease Is Safe and Immunogenic"],"prefix":"10.1128","volume":"12","author":[{"given":"Ingeborg S.","family":"Aaberge","sequence":"first","affiliation":[{"name":"Division of Infectious Disease Control, Norwegian Institute of Public Health (NIPH), Oslo, Norway"},{"name":"Chiron S.r.l., Siena, Italy"},{"name":"Chiron B.V., Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Oster","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease Control, Norwegian Institute of Public Health (NIPH), Oslo, Norway"},{"name":"Chiron S.r.l., Siena, Italy"},{"name":"Chiron B.V., Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oddveig S.","family":"Helland","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease Control, Norwegian Institute of Public Health (NIPH), Oslo, Norway"},{"name":"Chiron S.r.l., Siena, Italy"},{"name":"Chiron B.V., Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Cathrine","family":"Kristoffersen","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease Control, Norwegian Institute of Public Health (NIPH), Oslo, Norway"},{"name":"Chiron S.r.l., Siena, Italy"},{"name":"Chiron B.V., Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen","family":"Ypma","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease Control, Norwegian Institute of Public Health (NIPH), Oslo, Norway"},{"name":"Chiron S.r.l., Siena, Italy"},{"name":"Chiron B.V., Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. Arne","family":"H\u00f8iby","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease Control, Norwegian Institute of Public Health (NIPH), Oslo, Norway"},{"name":"Chiron S.r.l., Siena, Italy"},{"name":"Chiron B.V., Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Berit","family":"Feiring","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease Control, Norwegian Institute of Public Health (NIPH), Oslo, Norway"},{"name":"Chiron S.r.l., Siena, Italy"},{"name":"Chiron B.V., Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanne","family":"N\u00f8kleby","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease Control, Norwegian Institute of Public Health (NIPH), Oslo, Norway"},{"name":"Chiron S.r.l., Siena, Italy"},{"name":"Chiron B.V., Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1586\/14760584.1.1.75","volume":"1","year":"2002","unstructured":"Bethell, D., and A. J. Pollard. 2002. Meningococcal vaccines. Expert Rev. Vaccines1:75-84.","journal-title":"Expert Rev. Vaccines"},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/0140-6736(91)91961-S","volume":"338","year":"1991","unstructured":"Bjune, G., E. A. H\u00f8iby, J. K. Gr\u00f8nnesby, O. Arnesen, J. H. Fredriksen, A. Halstensen, et al. 1991. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet338:1093-1096.","journal-title":"Lancet"},{"key":"e_1_3_2_4_2","first-page":"5","volume":"9","year":"2004","unstructured":"Cano, R., A. Larrauri, S. Mateo, B. Alcal\u00e1, C. Salcedo, and J. A. V\u00e1zquez. 2004. Impact of the meningococcal C conjugate vaccine in Spain: an epidemiological and microbiological decision. Euro Surveill.9:5-6.","journal-title":"Euro Surveill."},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1017\/S0950268898001848","volume":"122","year":"1999","unstructured":"Connolly, M., N. Noah, and the European Meningitis Surveillance Group. 1999. Is group C meningococcal disease increasing in Europe? A report of surveillance of meningococcal infection in Europe 1993-6. Epidemiol. Infect.122:41-49.","journal-title":"Epidemiol. Infect."},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0163-4453(81)80009-6","volume":"3","year":"1981","unstructured":"De Wals, P., L. Hertoghe, I. Borlee-Grimee, S. De Maeyer-Cleempoel, G. Reginster-Haneuse, A. Dachy, et al. 1981. Meningococcal disease in Belgium. Secondary attack rate among household, day-care nursery and pre-elementary school contacts. J. Infect.3(Suppl. 1):53-61.","journal-title":"J. Infect."},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1016\/j.vaccine.2005.01.050","volume":"23","year":"2005","unstructured":"Dyet, K., A. Devoy, R. McDowell, and D. Martin. 2005. New Zealand's epidemic of meningococcal disease described using molecular analysis: implications for vaccine delivery. Vaccine23:2228-2230.","journal-title":"Vaccine"},{"key":"e_1_3_2_8_2","unstructured":"Feiring B. L. M. N\u00e6ss J. Fuglesang E. Rosenqvist M. A. R. Bergsaker A. Haugan et al. 2004. Antibody responses against homologous and heterologous meningococcal serogroup B strains after a fourth dose of a meningococcal serogroup B OMV vaccine (MenBvac). Abstracts of the 14th International Pathogenic Neisseria Conference Milwaukee Wis. p. 154. (www.neisseria.org\n.)"},{"key":"e_1_3_2_9_2","first-page":"67","volume":"14","year":"1991","unstructured":"Fredriksen, J. H., E. Rosenqvist, E. Wedege, K. Bryn, G. Bjune, L. O. Fr\u00f8holm, et al. 1991. Production, characterization and control of MenB-vaccine \u201cFolkehelsa\u201d: an outer membrane vesicle vaccine against group B meningococcal disease. NIPH (Natl. Inst. Public Health) Ann.14:67-79.","journal-title":"NIPH (Natl. Inst. Public Health) Ann."},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/CDLI.5.4.479-485.1998"},{"key":"e_1_3_2_11_2","first-page":"147","volume":"14","year":"1991","unstructured":"H\u00f8iby, E. A., E. Rosenqvist, L. O. Fr\u00f8holm, G. Bjune, B. Feiring, H. N\u00f8kleby, et al. 1991. Bactericidal antibodies after vaccination with the Norwegian meningococcal serogroup B outer membrane vesicle vaccine: a brief survey. NIPH (Natl. Inst. Public Health) Ann.14:147-155.","journal-title":"NIPH (Natl. Inst. Public Health) Ann."},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1086\/517385","volume":"177","year":"1998","unstructured":"Martin, D. R., S. J. Walker, M. G. Baker, and D. R. Lennon. 1998. New Zealand epidemic of meningococcal disease identified by a strain with phenotype B:4:P1.4. J. Infect. Dis.177:497-500.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/cdli.4.2.156-167.1997"},{"key":"e_1_3_2_14_2","first-page":"284","year":"2002","unstructured":"N\u00e6ss, L. M., T. Tangen, A. C. Kristoffersen, I. S. Aaberge, E. A. H\u00f8iby, and E. Rosenqvist. 2002. Immunogenicity of a combination of two different outer membrane protein based meningococcal group B vaccines. In D. A. Caugant and E. Wedege (ed.), Abstracts of the 13th International Pathogenic Neisseria Conference, Oslo, Nordberg Aksidenstrykkeri AS, Oslo, Norway, p. 284.","journal-title":"Abstracts of the 13th International Pathogenic Neisseria Conference, Oslo, Nordberg Aksidenstrykkeri AS, Oslo, Norway,"},{"key":"e_1_3_2_15_2","first-page":"95","volume":"14","year":"1991","unstructured":"N\u00f8kleby, H., and B. Feiring. 1991. The Norwegian meningococcal group B outer membrane vesicle vaccine: side effects in phase II trials. NIPH (Natl. Inst. Public Health) Ann.14:95-102.","journal-title":"NIPH (Natl. Inst. Public Health) Ann."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.63.12.4642-4652.1995"},{"key":"e_1_3_2_17_2","first-page":"323","volume":"92","year":"1998","unstructured":"Rosenqvist, E., E. A. H\u00f8iby, G. Bjune, A. Aase, A. Halstensen, A. K. Lehmann, et al. 1998. Effect of aluminium hydroxide and meningococcal serogroup C capsular polysaccharide on the immunogenicity and reactogenicity of a group B Neisseria meningitidis outer membrane vesicle vaccine. Dev. Biol. Stand.92:323-333.","journal-title":"Dev. Biol. Stand."},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.26.8.1543-1548.1988"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/CDLI.8.3.616-623.2001"},{"key":"e_1_3_2_20_2","unstructured":"N. Z. Med. J. 2004"},{"key":"e_1_3_2_21_2","unstructured":"N. Z. Med. J. 2004"},{"key":"e_1_3_2_22_2","first-page":"1520","volume":"281","year":"1999","unstructured":"Tappero, J. W., R. Lagos, A. M. Ballesteros, B. Plikaytis, D. Williams, J. Dykes, et al. 1999. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines. A randomized controlled trial in Chile. JAMA281:1520-1527.","journal-title":"JAMA"},{"key":"e_1_3_2_23_2","first-page":"125","volume":"1","year":"1998","unstructured":"Wenger, J. D., and B. A. Perkins. 1998. Patterns in the emergence of epidemic meningococcal disease, p. 125-136. In W. M. Scheld, D. Armstrong, and J. M. Hughes (ed.), Emerging infectious diseases, vol. 1. ASM Press, Washington, D.C.","journal-title":"Emerging infectious diseases"},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/00006454-200203000-00010","volume":"21","year":"2002","unstructured":"Zhang, Q., E. Pettitt, R. Burkinshaw, G. Race, L. Shaw, and A. Finn. 2002. Mucosal immune responses to meningococcal conjugate polysaccharide vaccines in infants. Pediatr. Infect. Dis. J.21:209-213.","journal-title":"Pediatr. Infect. Dis. J."}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CDLI.12.5.599-605.2005","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CDLI.12.5.599-605.2005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T20:36:12Z","timestamp":1627590972000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CDLI.12.5.599-605.2005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,5]]}},"alternative-id":["10.1128\/CDLI.12.5.599-605.2005"],"URL":"https:\/\/doi.org\/10.1128\/cdli.12.5.599-605.2005","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,5]]},"assertion":[{"value":"2004-12-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2005-03-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}